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Abstract
Introduction. Thyroid cancer (TC) is the most common malignant disease of the en-
docrine system. The incidence of the TC has been increasing worldwide, especially in 
female population. However, mortality from TC is low in both males and females. The 
objective of the paper was to determine and to analyze incidence and mortality trends of 
TC in males and females in the central Serbia in the period 1999-2014. 
Method. In this descriptive study data from the Serbian Cancer Registry were used. 
Crude and age-standardized rates (ASRs) of incidence and mortality were calculated. 
Trend and annual percentage change (APC) of the incidence and mortality rate with 
corresponding 95% confidence intervals (CI) were calculated by performing Joinpoint 
regression analyses.
Results. A total number of new cases of TC was 3113. TC was diagnosed in 2343 fe-
males and 770 males (female-to-male ratio, 3:1). A total number of fatal cases was 770 
(while 504 female and 266 male died from TC, female-to-male ratio, 1.9:1). TC was not 
common before 30 years of age. The highest incidence was recorded both in males and 
females aged 50-59. Joinpoint regression analysis showed the statistically significant in-
crease of ASRs of TC incidence in males in 1999-2014 period with APC 6.2% (95% CI: 
4.2-8.3, p < 0.001) and there was also significant increase of ASRs of TC incidence in fe-
males in the same study period with a APC 6.1% (95% CI: 4.2-8.0, p < 0.001). Joinpoint 
regression analysis showed an insignificant increase of ASRs of TC mortality in males 
with APC 2.4% (95% CI: -0.5-5.5, p = 0.1). There was an insignificant decrease of ASRs 
of TC mortality in females with APC -1.3% (95% CI: -4.4-1.9, p = 0.4).
Conclusion. The increasing trend of age-standardized incidence rates of TC both in 
males and females and decreasing trend of age-standardized mortality rates during the 
observed period were registered. Females had higher age-standardized incidence and 
mortality rates than males. Female to male ratio of incidence was 3:1 and for mortality 
1.9:1. Measures of primary and secondary prevention are needed.
INTRODUCTION
Thyroid cancer (TC) is one of the most common 
malignant diseases of the endocrine system [1]. World-
wide, TC represents 3.8% of all the new cancer cases, 
approximately 5% of all cancers in females and 2% in 
males [2]. Over the last 10 years, incidence rates of new 
TC have been growing by a 5.5% annual average [3] 
whereas TC mortality rates have been increasing by a 
0.8% annual average. Although TC has been considered 
an uncommon malignancy compared to other malig-
nant diseases, its incidence has been growing worldwide 
[3]. Its increase was registered in both genders, among 
many countries of the world such as the United States 
of America (USA), Canada, France, Great Britain, 
Italy, Israel, South Korea, and China [4-9]. The high-
est TC incidence rates in females (15 cases per 100 000 
per year) were recorded in France, Italy, and Croatia 
– conversely, the lowest rates were found in Greece, in 
Netherlands, and Romania. Age-adjusted TC incidence 
rates in females were significantly higher compared to 
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the ones in males, and the differences between the gen-
ders were somewhat lower in Hungary, Germany, and 
Portugal. TC incidence, particularly in females, varied 
according to geographical region with one of the lowest 
incidence rate recorded in Ireland [10].
According to the USA Surveillance, Epidemiology 
and End Results (SEER) registry, TC incidence tripled 
from 1975 to 2011, in contrast, as seen in Europe, with 
steady mortality trends [11]. TC is the ninth most com-
mon cancer among women, worldwide [11]. In Europe, 
it represents the fifth most common cancer in females 
while in Italy it is the second most common cancer in 
women younger than 45 years of age [12]. According 
to a study from South Korea, TC ranks as the leading 
cancer in females, and the fifth most common cancer 
in males [13]. About 2% of TC cases occur in children 
and teenagers. Females are more often affected than 
males (3:1 ratio) and are usually diagnosed at a younger 
age [14]. Furthermore, TC incidence rates are higher 
among females than males and among Caucasians than 
other major racial groups [15].
Results from several studies have suggested that di-
agnostic improvements cannot wholly account for ob-
served incidence trends, indicating a potential role of 
other factors, such as an increased environmental or 
hormonal exposure [16]. Known risk factors for TC are 
exposure to ionizing radiation (exposure through medi-
cal procedures, including x-rays, as well as radioactive 
fallout) especially in childhood, a history of goiter or 
thyroid nodules, family history of thyroid cancer, radio-
active exposure, certain rare genetic syndromes, and 
female gender [17].
Our study aimed to verify and analyze TC incidence 
and mortality trends in females and males in central 
Serbia during the period 1999-2014.
METHODS
A descriptive study was conducted by analyzing data 
on all new TC cases and deaths for TC in the popula-
tion of Central Serbia, excluding the territory of Au-
tonomous Province Vojvodina and Autonomous Prov-
ince of Kosovo and Metohija. The analysis was carried 
out based on the data extracted from publicly available 
Yearbooks of the Institute of Public Health of Serbia – 
Incidence and Mortality in Central Serbia, from 1999 
to 2014. Cancer registry in Vojvodina is completely is 
autonomous. Data about incidence and mortality for 
Kosovo and Metohija in the Cancer Register of the 
Republic Serbia has been missing since 1998. TC was 
coded according to the Tenth Revision of International 
Classification of Diseases-ICD-(codes C73)  [18]. Age-
standardized rates (ASRs) per 100 000 persons during 
the period 1999-2014 were calculated using the direct 
method according to the World Health Organization 
(WHO) World Standard population. Data regarding 
population of Central Serbia were obtained from 1991, 
2002, 2011 Censuses.
Trend and annual percentage change (APC) of the 
incidence and mortality rates with corresponding 95% 
confidence intervals (CI) were calculated by perform-
ing joinpoint regression analyses. The optimal number 
of Joinpoints was identified using the Monte Carlo 
permutation method. For regression analyses, the Join-
point Regression Program version 4.1.0 was used (avail-
able from: http://surveillance.cancer.gov/joinpoint). The 
trend was considered to be significant for an increase 
(positive change) or decrease (negative change) when 
the p-value was below 0.05 (p < 0.05).
RESULTS
From 1999 to 2014, the total number of new TC cas-
es reached 3113. It was diagnosed in 2343 males and 
770 males (female-to-male ratio, 3:1). The total number 
of fatal cases was 770 (504 females and 266 males died 
of thyroid cancer with a female to male ratio 1.9:1. 
Table 1 shows the age-standardized incidence and 
mortality rates (per 100 000 population) of TC in the 
male and female populations of Central Serbia for the 
period 1999-2014. In males, the number of new TC 
cases ranged from 27 (in 2000) to 80 (in 2012) and 
the average number of new cases was 48 and the ASRs 
of incidence in males ranged from 1.0 (in 2000) to 2.7 
(in 2013 and 2014). In females the number of new TC 
cases ranged from 78 to 215 with an annual average 
number of 144 new cases. The ARSs in females ranged 
from 2.8 (in 1999) to 8.0 (in 2013). The annual ARS 
and annual-adjusted mortality rates of TC increased 
during the study period in both males and females. In 
the period 1999-2014, annual ASR of mortality ranged 
from 0.3 (in 2003) to 0.9 (in 2013 and 2014).
Table 2 reports the distribution of TC cases by gender 
and age, in central Serbia from 1999 to 2014. A total 
of 29.2% of new TC cases occurred in the 20-49-year 
age group. More than one quarter (27.4%) of new cases 
were recorded in the 50-59-year age group. Of all pa-
tients, 17.9% were aged over 70 years at the time of 
diagnosis. In the 40-49-year age group, new TC cases 
were significantly more frequent among females than 
among males (17.1% vs 11.8%, p < 0.001). Conversely, 
in the oldest group (over 70 years), new TC cases were 
significantly more frequent in males compared to fe-
males (22.7% vs 16.1%, p < 0.001).
Figure 1 shows the incidence trend, based on age-
adjusted incidence rates in males and females, in the 
period 1999-2014, the Joinpoint analyses (world stan-
dard population) of TC in central Serbia, with annual 
percentage change (APC). Joinpoint regression analy-
sis showed the statistically significant increase of ASR 
for TC incidence in males during the 1999-2014 period 
with APC of 6.2% (95% CI: 4.2-8.3, p < 0.001). More-
over, a significant increase of ASR was also present for 
TC incidence in females during the same study period, 
with APC of 6.1% (95% CI: 4.2-8.0, p < 0.001).
Figure 2 displays TC mortality in males and females 
in the period 1999-2014, Joinpoint analysis (world stan-
dard population) in central Serbia, with annual percent-
age change (APC). Joinpoint regression analysis showed 
an insignificant increase of TC mortality in males dur-
ing 1999-2014 with APC of 1.52% (95% CI: 4.0-1.3, p = 
0.2). In addition, a non-significant decrease of TC mor-
tality was also present in females during the same study 
period with APC of -1.92% (95% CI: 0.4-1.8, p = 0.10).
Figure 3 shows TC mortality trend based on age-adjust-
ed mortality rates in the period 1999-2014, in males and 
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females, Joinpoint analyses (world standard population) 
in central Serbia, 1999-2014, with annual percentage 
change (APC). The Joinpoint regression analysis showed 
a non-significant ASR decrease of TC mortality in males 
during 1999-2014 with APC of 2.44% (95% CI: -0.5-5.5, 
p = 0.1). Also a non-significant ASR decrease of TC mor-
tality was present in females during the same study period 
with APC of -1.31% (95% CI: -4.4-1.9, p = 0.4).
DISCUSSION
In our study results have shown an increasing trend 
of the age-adjusted TC incidence rate both in males 
and females, during the observed 1999-2014 period. 
A statistically non-significant increasing trend of age-
adjusted TC mortality rate was found in males, and a 
non-significant decreasing trend of age-adjusted TC 
mortality rate was present in females. Indeed, females 
had higher annual age-adjusted incidence and mortality 
rates than males.
These results are in agreement with other studies, 
which have found a similar 3-to-1 ratio for females and 
males [5, 11, 12, 19, 20]. In agreement with findings 
from another study [8], which included 21 European 
countries, the average TC incidence rate ranged from 
1.8 up to 5.0 for males and females respectively, for 
the 1995-2002 period. According to the average age-
adjusted TC incidence rate in females (3.3 per 100 000 
persons), Serbia ranks as a country with average TC 
incidence rates in females, and low incidence rates in 
males (1 per 100 000 persons). An increase in TC inci-
dence in Serbia in both genders was found in the 1999-
2008 period. The highest increase in TC incidence was 
found in females aged 20 to 29 years while the highest 
incidence was found in the 50-59-year age group [21].
Table 1
Age-adjusted* incidence and mortality rates (per 100 000 population) of thyroid cancer in male and female population of Central 
Serbia, 1999-2014
Year Males Females
  No of 
cases
Incidence 
rate
No of 
deaths
Mortality 
rate
No of 
cases
Incidence 
rate
No of 
deaths
Mortality 
rate
1999 34 1.3 17 0.6 78 2.8 37 1.4
2000 27 1 17 0.6 87 3.1 40 1.4
2001 29 1.1 15 0.6 132 4.1 34 1.2
2002 33 1.2 17 0.6 104 3.7 25 0.9
2003 44 1.7 13 0.3 102 3.6 35 0.6
2004 41 1.5 15 0.6 133 4.8 35 1.3
2005 36 1.4 12 0.5 123 4.4 27 1
2006 45 1.7 19 0.7 153 5.5 35 1.3
2007 67 2.6 19 0.7 156 7.1 37 1.3
2008 38 1.5 16 0.6 193 7 35 0.9
2009 42 1.6 10 0.4 160 5.8 24 1
2010 58 2.2 16 0.6 161 5.9 27 1
2011 54 2.1 16 0.6 142 5.2 28 0.8
2012 80 2.6 19 0.7 181 6.8 24 0.5
2013 70 2.7 22 0.9 215 8 20 0.7
2014 69 2.7 23 0.9 183 6.8 41 1.5
*Standardization according to world population WHO.
Table 2
Distribution of thyroid cancer cases by gender and age, Central Serbia, 1999-2014
Age-group Total
N = 3113
Male
N = 770
Female
N = 2343
p-value1
0-19 109 3.5% 24 3.1% 85 3.6% 0.448
20-29 151 4.9% 43 5.8% 108 4.6% 0.274
30-39 293 9.5% 59 7.6% 234 9.9% 0.055
40-49 491 15.9% 91 11.8% 400 17.1% < 0.001
50-59 849 27.4% 199 25.8% 650 27.7% 0.305
60-69 648 20.9% 179 23.2% 469 20.0% 0.055
≥ 70 553 17.9% 175 22.7% 378 16.1% < 0.001
1Chi squared test.
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Between 1994 and 2007, TC incidence more than 
doubled in Vermont, USA [5]. The age-adjusted TC in-
cidence in Vermont was 8.0 per 100 000 persons with 
a female-to-male ratio of 3.1:1, while mortality rate 
was 0.5 per 100 000 persons. It was concluded that in-
cidence among females peaked at 30-59 years of age, 
TC more than doubled in females aged between 30 and 
59 years over the study period and the incidence even 
increased in males.
In our study, over the observed period, TC was reg-
istered in both genders. The steep increase of TC inci-
dence after 30 years of age was observed in both females 
and males. The highest number of new TC cases was 
registered in the 50-69-year age group in both females 
(47%) and males (37%). These findings are consistent 
with similar published data, according to which, in Ser-
bia in the 1999-2008 period, TC incidence increased 
substantially in both genders with the highest increase 
in 2007 for the 50-59-year age group. TC was three-fold 
higher in females (CR 4.7:1.5) than in males [21].
However, this increase of TC incidence has yet to be 
explained. Potentially, it could be due to enhanced diag-
nostic procedures. Indeed, the development and use of 
more sophisticated TC diagnostic technologies, which 
began in the late 1990s through the early 2000s, may 
have led to an over diagnosis of TC [16]. Conversely, 
TC mortality is stable and low [1, 14]. It is well-known 
that TC patients have a high survival rate [23]. Five-
year relative survival for thyroid cancer ranged from 
73% in Belgium to 96% in Iceland with a European av-
erage of 83% [8]. According to the GLOBOCAN 2012 
database [22], TC mortality varied little, with slight dif-
ferences between the sexes. In females, TC mortality 
rates were between 0.2 to 1.0 per 100 000 person-years, 
and in males, the range in TC mortality rates was from 
0.1 to 0.7 per 100 000 person-years [22].
Figure 1
Incidence trend based on age-adjusted incidence rates in 
males and females in the period 1999-2014, Joinpoint analyses 
(world standard population) of thyroid cancer in central Serbia, 
with annual percentage change (APC).
WASR: World-Age-Adjusted Rate
Figure 3
Mortality trend of thyroid cancer based on age-adjusted mor-
tality rates in the period 1999-2014, in males and females, Join-
point analyses (world standard population) in central Serbia, 
1999-2014, with annual percentage change (APC).
Figure 2
Mortality of thyroid cancer in males and females in the period 
1999-2014, Jointpoint analysis (world standard population) in 
central Serbia, with annual percentage change (APC).
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According to the findings reported by Olaleye et al. 
[23], the highest increase in TC was observed in the 50-
59-year age group. The authors also found a significant 
increase in the 20-39-year age group, whereas we found 
the highest incidence increase between the 20-29-
year and 30-39-year age groups, showing two-fold and 
four-fold increases in females and males, respectively. 
In Lithuania, a steep increase in incidence at the age 
of 30 years was observed in females [19]. The results 
from Croatia have shown that females had higher TC 
incidence than females in other European countries, 
including Serbia. Between of 1988-2010, TC was diag-
nosed in 5453 females and 1355 males (female-to-male 
ratio, 4:1), while 542 females and 282 males died from 
this malignant disease (female-to-male ratio, 2:1) [24-
26]. The age-adjusted incidence rate among females in 
Finland was more than two-fold higher compared to 
that reported in Denmark in both time periods (1973-
1977 and 1998-2002) [1].
It is also noteworthy that despite the wide inter-coun-
try variation in age-adjusted incidence rates, a consis-
tent female-to-male ratio of three-to-one is observed 
within most of the countries included in the interna-
tional comparison, in both the earlier (1973-1977) and 
later (1998-2002) periods [27, 28]. Possible explana-
tions for the disparities between males and females with 
sporadic TC are biological sex differences, differential 
screening patterns, or gender-specific behavioral differ-
ences. One hypothesized mechanism is that increased 
levels of female hormones during reproductive years, 
due to pregnancy that increases thyroid stimulating 
hormone (TSH) levels, potentially lead to thyroid dys-
plasia and then to cancer [20, 28]. 
According to our results, discrepancies were ob-
served between age-adjusted incidence rates in females 
and low rates in males. The TC is more common in fe-
males and the higher incidence might attribute to an 
increased detection of the disease in women than in 
men. Also a decline in mortality is due to the changes 
in diagnosis, treatment, and risk factors. These findings 
are in constancy with the literature [6, 18, 20, 23, 28]. 
Over the last three decades, TC incidence increased 
substantially also in the USA [5, 9, 11, 29]. Between 
1998 and 2002, the highest age-adjusted rates were re-
corded in the USA and Israel in males (3.5 per 100 000 
persons for both countries) and in females (10.0 per 
100 000 persons and 12.1 per 100 000 persons, respec-
tively), while the lowest rates were recorded in Uganda 
in males (0.5 per 100 000 persons) and in females (1.5 
per 100 000 persons) [15, 16]. According to the Na-
tional cancer registry of Ireland during the period 2006-
2010, TC comprised just 0.9% of all invasive cancers 
registered (1.4% of all female cancers and 0.5% of male 
cancers). Incidence rates increased significantly in both 
sexes, especially in females [10].
Trends in TC incidence and mortality vary widely by 
country, but for most areas of the world, the data in-
dicate an upward trend in incidence and a downward 
trend in mortality. Those trends are supported by the 
present analysis of TC mortality and incidence, glob-
ally. The analyses were based on data maintained by the 
World Health Organization (1970-2012) and Cancer 
Incidence in Five Continents (1960-2007).
Limitations
Several limitations should be considered, such as lack 
of data regarding histological types of thyroid cancer, 
variations in tumor classifications related to analyses of 
registry data and possible incomplete data collection.
CONCLUSIONS
Our results highlighted a significantly increasing 
trend of age-adjusted TC incidence rates both in males 
and females, during the period 1999-2014. A statistical-
ly non-significant increasing trend of age-adjusted TC 
mortality rates in males and non-significant decreasing 
trend of age-adjusted mortality rates in females were 
observed during the observed period. Females had 
higher annual age-adjusted incidence and mortality 
rates compared to males with female-to-male ratios of 
3:1 for incidence and 1.9:1 for mortality.
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